drugset / Trial / NCT01496976
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
Phase 2
Completed
45 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to see if ofatumumab with methylprednisolone followed by additional treatment with ofatumumab and lenalidomide can help people with Chronic Lymphocytic Leukemia (CLL) get rid of their CLL for a long period of time. Researchers also want to find out if the combination of ofatumumab with methylprednisolone followed by additional treatment with ofatumumab and lenalidomide is safe and tolerable.
Timeline
- Start
- 2012-03-30
- Primary completion
- 2021-10-06
- Completion
- 2024-09-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | — | — |
| Subject | Methylprednisolone | Other / unclassified | 1000 mg/m2 | Intravenous |
| Subject | Ofatumumab | Monoclonal antibody | — | — |